Immunosuppressive strategies in face and hand transplantation: a comprehensive systematic review of current therapy regimens and outcomes.

face transplant hand transplant immunosuppressive therapy outcome vascularized composite allograft (VCA)

Journal

Frontiers in transplantation
ISSN: 2813-2440
Titre abrégé: Front Transplant
Pays: Switzerland
ID NLM: 9918573988006676

Informations de publication

Date de publication:
2024
Historique:
received: 05 01 2024
accepted: 21 02 2024
medline: 12 7 2024
pubmed: 12 7 2024
entrez: 12 7 2024
Statut: epublish

Résumé

Recipients of Vascularized Composite Allotransplants require effective immunosuppressive therapy to prevent graft rejection. This systematic review summarizes the current body of literature on immunosuppressive regimens used in face and hand transplants while summarizing their outcome in terms of rejection, renal failure, and infections. A systematic search of electronic databases was conducted to identify relevant studies from 1998 until July 1st, 2023. We included all studies that discussed immunosuppressive strategies in face and hand transplant recipients according to PRISMA. The standard triple maintenance therapy was mostly adjusted due to nephrotoxicity or high incidence of rejection. The most common alternative treatments utilized were sirolimus (25/91; 27.5%) or everolimus (9/91; 9.9%) following hand- and photophoresis (7/45; 15.6%), sirolimus (5/45; 11.1%) or belatacept (1/45; 2.2%) following face transplantation. Episodes of rejection were reported in 60 (65.9%) of hand- and 33 (73%) of face transplant patients respectively. Graft loss of 12 (13.2%) hand and 4 (8.9%) face transplants was reported. Clinical CMV infection was observed in 6 (6.6%) hand and 7 (15.5%) face transplant recipients. Based on the herein presented data, facial grafts exhibited a heightened incidence of rejection episodes and CMV infections. Facial mucosa adds complexity to the immunological graft composition highlighting the need of individualized immunosuppressive regimens and further research.

Sections du résumé

Background UNASSIGNED
Recipients of Vascularized Composite Allotransplants require effective immunosuppressive therapy to prevent graft rejection. This systematic review summarizes the current body of literature on immunosuppressive regimens used in face and hand transplants while summarizing their outcome in terms of rejection, renal failure, and infections.
Methods UNASSIGNED
A systematic search of electronic databases was conducted to identify relevant studies from 1998 until July 1st, 2023. We included all studies that discussed immunosuppressive strategies in face and hand transplant recipients according to PRISMA.
Results UNASSIGNED
The standard triple maintenance therapy was mostly adjusted due to nephrotoxicity or high incidence of rejection. The most common alternative treatments utilized were sirolimus (25/91; 27.5%) or everolimus (9/91; 9.9%) following hand- and photophoresis (7/45; 15.6%), sirolimus (5/45; 11.1%) or belatacept (1/45; 2.2%) following face transplantation. Episodes of rejection were reported in 60 (65.9%) of hand- and 33 (73%) of face transplant patients respectively. Graft loss of 12 (13.2%) hand and 4 (8.9%) face transplants was reported. Clinical CMV infection was observed in 6 (6.6%) hand and 7 (15.5%) face transplant recipients.
Conclusions UNASSIGNED
Based on the herein presented data, facial grafts exhibited a heightened incidence of rejection episodes and CMV infections. Facial mucosa adds complexity to the immunological graft composition highlighting the need of individualized immunosuppressive regimens and further research.

Identifiants

pubmed: 38993787
doi: 10.3389/frtra.2024.1366243
pmc: PMC11235358
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1366243

Informations de copyright

© 2024 Huelsboemer, Boroumand, Kochen, Dony, Moscarelli, Hauc, Stögner, Formica, Pomahac and Kauke-Navarro.

Déclaration de conflit d'intérêts

LH is receiving an individual research grant by the German Research Foundation (DFG). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Lioba Huelsboemer (L)

Division of Reconstructive and Plastic Surgery, Yale School of Medicine, New Haven, CT, United States.

Sam Boroumand (S)

Division of Reconstructive and Plastic Surgery, Yale School of Medicine, New Haven, CT, United States.

Alejandro Kochen (A)

Division of Reconstructive and Plastic Surgery, Yale School of Medicine, New Haven, CT, United States.
Regenerative Wound Healing Center, Yale School of Medicine, New Haven, CT, United States.

Alna Dony (A)

Division of Reconstructive and Plastic Surgery, Yale School of Medicine, New Haven, CT, United States.
School of Medicine, University of Leeds, Leeds, United Kingdom.

Jake Moscarelli (J)

Division of Reconstructive and Plastic Surgery, Yale School of Medicine, New Haven, CT, United States.

Sacha C Hauc (SC)

Division of Reconstructive and Plastic Surgery, Yale School of Medicine, New Haven, CT, United States.

Viola A Stögner (VA)

Division of Reconstructive and Plastic Surgery, Yale School of Medicine, New Haven, CT, United States.

Richard N Formica (RN)

Department of Medicine, Section of Nephrology and Transplantation, Yale School of Medicine, New Haven, CT, United States.

Bohdan Pomahac (B)

Division of Reconstructive and Plastic Surgery, Yale School of Medicine, New Haven, CT, United States.

Martin Kauke-Navarro (M)

Division of Reconstructive and Plastic Surgery, Yale School of Medicine, New Haven, CT, United States.

Classifications MeSH